Effect of Intravitreal Bevacizumab on Corneal Endothelium
NCT01726790 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 37
Last updated 2012-11-15
Summary
To evaluate corneal endothelium cell change after intravitreal Bevacizumab injection
Conditions
- Corneal Endothelial Cell Loss
Sponsors & Collaborators
-
Khon Kaen University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-08-31
- Primary Completion
- 2013-06-30
- Completion
- 2013-10-31
Countries
- Thailand
Study Locations
More Related Trials
-
Intralesional Bevacizumab Injection on Primary Pterygium
NCT01380678 ·Status: UNKNOWN ·Phase: PHASE3
-
Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)
NCT00370786 ·Status: COMPLETED ·Phase: PHASE3
-
Study on the Biomarkers of Anti-VEGF Treatment for Choroidal Neovascularization
NCT06243406 ·Status: NOT_YET_RECRUITING
-
Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy
NCT00423059 ·Status: COMPLETED ·Phase: NA
-
Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study
NCT02015351 ·Status: COMPLETED ·Phase: NA
-
Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
NCT01256580 ·Status: WITHDRAWN ·Phase: NA
-
Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy
NCT04511715 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Intravitreal Anti-vascular Endothelial Growth Factor Administration and Its Influence on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular Degeneration
NCT03680326 ·Status: COMPLETED
-
Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
NCT00383812 ·Status: UNKNOWN ·Phase: NA
-
Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema
NCT01342159 ·Status: COMPLETED ·Phase: NA
-
The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery
NCT02767219 ·Status: COMPLETED ·Phase: PHASE3
-
Intravitreal Bevacizumab for Inflammatory Neovascular Membranes
NCT00407121 ·Status: WITHDRAWN ·Phase: PHASE3
-
Efficacy of Retreatments With Intravitreal Bevacizumab
NCT00406744 ·Status: TERMINATED ·Phase: PHASE3
-
Corneal Thinning During Topical Bevacizumab Therapy
NCT00515684 ·Status: WITHDRAWN ·Phase: NA
-
Bleb Vascularity Change After Subconjunctival Injection Bevacizumab
NCT00815594 ·Status: UNKNOWN ·Phase: PHASE4
-
Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)
NCT01327222 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration
NCT01027468 ·Status: COMPLETED ·Phase: NA
-
Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization
NCT03971162 ·Status: COMPLETED ·Phase: NA
-
Major and Macular Branched Retinal Venous Occlusion
NCT01219205 ·Status: COMPLETED ·Phase: NA
-
Acute Changes in Intraocular Cytokines After Intravitreal Bevacizumab
NCT01439178 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea
NCT01501760 ·Status: COMPLETED ·Phase: PHASE3
-
Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy
NCT01854593 ·Status: COMPLETED ·Phase: PHASE4
-
Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT
NCT03648814 ·Status: RECRUITING ·Phase: NA
-
Comparison of Subconjuctival Versus Topical Bevacizumab as Adjunct Therapy to Trabeculectomy
NCT01425112 ·Status: COMPLETED ·Phase: NA
-
Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema
NCT00417716 ·Status: WITHDRAWN ·Phase: PHASE3